Levosimendan Stada

Levosimendan, the active ingredient in Levosimendan Stada, is a calcium sensitizer presented as an intravenous formulation for intravenous use. It is employed in the management of acute decompensated heart failure to enhance cardiac contractility and support circulation in patients with severe ventricular dysfunction.

GNH USA supplies Levosimendan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is indicated for conditions involving acute cardiac insufficiency where rapid improvement of contractility is required. - Acute decompensated heart failure: increases cardiac output and relieves symptoms of low output. - Severe left ventricular dysfunction: improves myocardial performance during acute episodes. - Post‑cardiac surgery low‑output syndrome: supports hemodynamics when conventional therapy is insufficient.

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Hypotension: reduction in blood pressure, especially after infusion start. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Arrhythmias: ventricular or atrial ectopic beats. - Myocardial ischemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Pulmonary edema: fluid accumulation in lungs. - Liver enzyme elevation: transient increase in transaminases.

When using Levosimendan, several safety considerations should be observed. - Hemodynamic monitoring: continuous blood pressure and cardiac rhythm assessment is essential. - Concomitant vasodilators: avoid excessive hypotension by adjusting doses. - Pre‑existing arrhythmias: evaluate risk before initiation. - Renal or hepatic impairment: consider dose adjustments and close observation. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medications that affect cardiovascular function.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Concurrent use with other inotropes (e.g., dobutamine): risk of excessive cardiac stimulation. - Potent vasodilators (e.g., nitroglycerin): can cause severe hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate volume depletion and hypotension. - Beta‑blockers: may blunt desired inotropic effect. - Anticoagulants: monitor for bleeding if hypotension occurs.